2 A mechanism possibly underlying the development of sustained seizure-like activity is the loss of synaptically released y-aminobutyric acid (GABA). Drugs which increase the amount of GABA available in presynaptic endings might thus be useful in the treatment of these therapeutically complicated forms of epilepsy. 3 Therefore, we studied the effects of various substances increasing GABA-mediated inhibition on early and late forms of epileptiform activity. GABA and the GABAA receptor agonist muscimol blocked both the pharmacosensitive discharges in the hippocampus and entorhinal cortex as well as the late recurrent discharges in the medial entorhinal cortex. The GABAB receptor agonist baclofen blocked the recurrent short discharges very potently, but did not consistently block seizure-like events and late recurrent discharges in the entorhinal cortex. 4 GABA uptake blockers showed a differential potency to block the various discharge patterns.
Introduction
Many anticonvulsant drugs act by potentiating y-aminobutyric acid (GABA)-mediated inhibition in the nervous system (Macdonald & McLean, 1986) . However, some of the substances increasing GABAA receptor-mediated responses have severe sedative side-effects (barbiturates) or lead to tolerance upon prolonged treatment (benzodiazepines). Therefore, alternative strategies have been chosen to strengthen GABAmediated inhibition.
Special interest has been devoted to GABA uptake blockers which exert their anticonvulsant effects by prolonging the duration of inhibitory postsynaptic potentials (Rekling et al., 1990; Fink Jensen et al., 1992; Gram, 1994; Suzdak & Jansen, 1995; Draguhn & Heinemann, unpublished) . They are highly efficient anticonvulsants in several animal models of chronic epilepsy (Heit & Schwark, 1988; Suzdak, 1994; Walton et al., 1994; Suzdak & Jansen, 1995; Smith et al., 1995) . Tiagabine, a lipophilic derivative of nipecotic acid (NPA) is presently tested as add-on therapy against complex partial seizures in man (Gram, 1994) . Alterations of the GABA uptake system in chronic epileptic syndromes have been found both in animal models and in man. Recent evidence suggests that the GABA uptake is reduced in tissue from animals and humans with ' Author for correspondence. chronic temporal lobe epilepsy (Janjua et al., 1991; During et al., 1995) . This should lead to prolonged synaptic inhibition and might reflect an adaptation to hyperexcitability. GABA uptake molecules can release the transmitter from cells by reversed function under certain ionic and electrical conditions (Attwell et al., 1993; Cammack et al., 1994) . It has therefore been suggested that the loss of reverse transport capacity might reduce the inhibitory tone in hyperactive tissue and thus aggravate seizures (During et al., 1995) .
Acute neuronal hyperactivity is characterized by enhanced synaptic transmission and leads to an augmented release of excitatory as well as inhibitory neurotransmitters (Sayin et al., 1995) . Chronic epilepsy can also be accompanied by enhanced inhibitory transmission (Whittington & Jefferys, 1994) . Following synaptic release, GABA is transported into presynaptic endings as well as into glia cells where some of the transmitter is metabolized by the GABA transaminase (Schousboe, 1982) . The relative amount of neuronal vs. glial GABA uptake is not known. This metabolic shunt, however, might lead to a progressive loss of synaptically available GABA during prolonged epileptic hyperactivity. This may result in transition to prolonged and therapeutically complicated forms of status epilepticus. Experimental and clinical evidence for this concept comes from the effect of y-vinyl-GABA (vigabatrin). This substance is an irreversible blocker of the GABA transaminase and is a potent antiepileptic drug both in vitro and in human patients British Journal of Phamacology (1996 ) 119, 569-577 (Ben-Menachem, 1995 Halonen et al., 1995; Buchanan, 1993) . Conventional GABAergic drugs acting on GABAA receptors will become progressively less potent if the presynaptic GABA content and consequently the amount of synaptically released GABA decreases. Indeed, severe forms of epilepsy like status epilepticus are frequently resistant towards these agents.
In such cases, it might be therapeutically useful to enhance the amount of transmitter in the neuronal GABA pool by selectively blocking the glial uptake or by adding GABA receptor agonists. We therefore tested various GABAergic drugs on acute and prolonged epileptiform neuronal discharges. We employed the low-Mg2" model of temporal lobe epilepsy in combined entorhinal cortex-hippocampal brain slices of rats. Whereas early stages of epileptiform activity in this model can be blocked by clinically available antiepileptic drugs (AEDs), the later form of discharges in the entorhinal cortex is resistant to presently employed AEDs (Walther et al., 1986; Zhang et al., 1995) . Based on the assumption that prolonged hyperactivity might result in reduced availability of GABA we analyzed the effect of GABA receptor agonists as well as various GABA uptake blockers on the early and late patterns of epileptiform field potentials.
Methods

Slice preparation
The experiments were performed as described previously (Dreier & Heinemann, 1990) . In brief, combined entorhinal cortex-hippocampal slices (400 um) containing the temporal cortex area 3, the perirhinal cortex, the entorhinal cortex, the subiculum, the dentate gyrus and the ventral hippocampus were prepared in a nearly horizontal plane from male or female adult Wistar rats (150-250 g) decapitated under deep ether anaesthesia. The slices were placed in an interface chamber and were continuously perfused (1.5 -2 ml min-') with prewarmed (35°C) artificial cerebrospinal fluid (ACSF) which contained (in mM): NaCl 124, KCl 3, MgSO4 1.8, CaCl2 1.6, NaH2PO4 1.25, NaHCO3 26, and glucose 10 (pH 7.4). The ASCF was saturated with carbogen (95% 02, 5% C02). MgSO4 was omitted in the nominally Mg2+-free ACSF. Drugs were added to the Mg2+-free ACSF after onset of epileptiform activity.
Before the experiment was started the slices were allowed to recover from their preparation for at least one hour. 
GABA receptor agonists
The natural agonist GABA reduced the frequency of the recurrent short discharges in area CAl in a concentrationdependent manner. Whereas 1.0 mm showed only little effect, 2.5 mM GABA blocked the RSDs in two thirds of the experiments. With 5 mM, in almost all slices tested RSDs were blocked (Figures la and 2a) . The seizure-like events in the mEC were more sensitive to GABA-application than the RSDs in the hippocampus. Here, the antiepileptic effect started at 0.5 mM GABA and the discharges were completely blocked at 2.5 mM (Figures lb and 2a) (Figure 2c ). Similar to muscimol, baclofen could reverse LRDs to SLEs in all 19 experiments, but the resulting SLEs were slightly atypical lacking a marked clonic-like discharge pattern in the field potentials (not shown). Like the initial SLEs these discharges were also resistant towards baclofen. A comparison of the main effects of the GABA receptor agonists is shown in Figure 2 .
GABA uptake inhibitors
The GABA uptake blocker, (± )-nipecotic acid (NPA) reduced the frequency of the recurrent short discharges in the hippocampus concentration-dependently. The antiepileptic effect started at 1 mM and at 5 mM NPA the RSDs were completely blocked (Figure 4a ). When NPA (1-2.5 mM) was applied after the appearance of SLEs in the mEC it also suppressed this activity (Figure 4a ). Nipecotic acid (1-5 mM) reduced the frequency of LRDs in the mEC in a concentration-dependent manner. At the same time, the amplitude and duration of single LRDs were increased. A complete block was reached at 5 mM (±)-nipecotic acid (Figures 3d and 4a) . In contrast to the effect of the GABA receptor agonists, we never observed a transition from LRDs back to the pattern of seizure-like events during the application of nipecotic acid.
The GABA uptake blocker ,B-alanine was slightly less potent than (±)-nipecotic acid in suppressing the different forms of epileptiform activity (Figure 4b ). The antiepileptic effect on the hippocampal recurrent short discharges started at a concentration of 1 mM and at 5 mM the RSDs were always blocked. SLEs were suppressed by ,B-alanine with lower potency than by NPA, but at 5 mm a complete block was achieved. The late recurrent discharges in the mEC required even higher concentrations for suppression starting at 2.5 mM.
In 4 out of 10 slices there was no complete block of this late form of activity even at 5 mM ,B-alanine (Figure 4b ).
Tiagabine was studied at concentrations between 10 and 250 gM. Hippocampal recurrent short discharges were blocked or reduced in frequency by 10 gM tiagabine in 17 of 24 experiments (Figures 3a and 4c) . Surprisingly, the substance lost its efficacy at higher concentrations and developed a proconvulsive effect at 250 pM (Figures 3a and 4c) . In 4 slices which had shown a reduction of RSD frequency by 10 gM tiagabine, the subsequent application of 50 pM had no effect (RSD frequency 107.9+17.3% of control) and 250 yM tiagabine even increased the frequency of the discharges to 153.1+30.3% (Figures 3a and 4c) . In 4 experiments where 10 gM tiagabine had no effect, increasing the concentration to 250 gM also had no influence on the activity. In contrast, SLEs in the entorhinal cortex were always blocked by 10 pM tiagabine (Figures 3b and 4c) . The recovery was rather slow and upon washout of the substance the first SLE reappeared after 40 to 120 min. The uptake blocker was also applied to slices showing LRDs in the mEC. We tested concentrations between 10 and 250 gM. At none of the concentrations tested (10, 50, and 250 gM) was tiagabine able to influence the duration, amplitude or frequency of entorhinal LRDs (Figures 3c and 4c) . The effects of the various GABA uptake blockers are summarized in Figure Sd) . Application of bicuculline to slices already displaying LRDs increased the frequency of these events by 118% (n = 4; Figure Se) .
The role of GABAB-mediated inhibition was analyzed fur- . The seizure-like events in the entorhinal cortex are sensitive to phenytoin and carbamazepine, to GABAA receptor modulators like benzodiazepines and barbiturates, and to GABAA-and GABAB-receptor agonists (Jones, 1989; Heinemann et al., 1994) . The most interesting discharge patterns are the short negative-going field potentials in the entorhinal cortex (late recurrent discharges, LRDs) which occur upon prolonged washout of Mg2" (Dreier & Heinemann, 1990) . These events are insensitive to clinically employed anticonvulsants and can therefore serve as a test system for drugs developed against pharmacoresistant forms of epilepsy (Zhang et al., 1995) .
GABAergic inhibition plays an important role in the maintenance of neuronal function even during epileptiform activity. Block of the GABAA receptor aggravated the epileptiform activity in our experiments as previously described (Jones, 1988; Jones & Lambert, 1990) . The highly potent GABAB receptor antagonist CGP 55845A (Jarolimek et al., 1993) had no proconvulsant effect in the EC but increased the frequency of RSDs in CAl. Thus, GABAB-mediated inhibition is more important in CAl than in the EC in the low-Mg2+-model; this has also been found in 4-aminopyridine-induced seizures (Jones, 1994) . The aim of the present study was to examine further the antiepileptic potency of different GABAergic drugs on the epileptiform activities. (22 min) clearly reduced the frequency of the hippocampal recurrent short discharges. After washout of the drug, recovery of the epileptiform discharges is visible. At 50 um (23 min) tiagabine showed no effect on the RSDs and at 250 ,UM (26 min) the frequency of the discharges was significantly increased. (b) At 10 uM, tiagabine suppressed the seizure-like events, which reappeared after washout of the substance. Note that tiagabine did not block the interictal-like activity in the entorhinal cortex. (c) Tiagabine showed no effect on the late epileptiform activity. In this experiment, tiagabine was applied at 50 gM for 23 min and subsequently at 250 gM for 26 min. (d) Nipecotic acid (5 mM) reversibly suppressed late recurrent discharges (LRDs) in the entorhinal cortex.
Effects of GABAergic drugs on LRDs
In contrast to clinically used antiepileptics, GABA suppressed the LRDs concentration-dependently. Both the GABAA and the GABAB receptor agonists, muscimol and baclofen, respectively consistently reversed LRDs to SLEs in all experiments. Thus, supplementing the tissue with GABA receptor agonists is an efficient antiepileptic mechanism for LRDs.
The second approach followed in our experiments was to strengthen inhibitory transmission by GABA uptake blockers. These drugs prolong the postsynaptic effects of GABA (Dingledine & Korn, 1985; Thompson & Giihwiler, 1992; Oh & Dichter, 1994; Roepstorff & Lambert, 1994; Draguhn & Heinemann, unpublished) . The three GABA uptake blockers tested in our experiments displayed diverse effects. Whereas nipecotic acid (NPA) and f-alanine were both able to suppress the LRDs, tiagabine failed to influence this activity even at very high concentrations (250 gM). Both fl-alanine and NPA had effective concentrations clearly above their apparent KD for uptake inhibition (Guastella et al., 1990; Borden et al., 1992; Liu et al., 1993) . However, Dingledine & Korn (1985) used similar high concentrations of NPA to prolong inhibitory postsynaptic potentials in CAl neurones. This discrepancy is possibly due to uptake of the substances and the slow equilibration time in brain slices (Muller et al., 1988) .
The recent cloning of cDNAs coding for GABA uptake molecules (GAT-1 to GAT-4) has revealed that tiagabine is a highly potent and selective inhibitor of the neuronally expressed GAT-l (Clark et al., 1992; Ikegaki et al., 1994; Borden et al., 1994) , whereas P-alanine and NPA act on a variety of transporters which might also be expressed in glia (Guastella et al., 1990; Clark et al., 1992; Liu et al., 1993; Borden et al., 1994) . Another specific feature of NPA is its ability to reverse GABA uptake and thereby enhance the extracellular amount of free GABA by a non-synaptic mechanism (Solis & Nicoll, 1992; Honmou et al., 1995) . Reversed uptake has been suggested to be a major inhibitory mechanism under pathophysiological conditions (Attwell et al., 1993; Cammack et al., 1994; During et al., 1995) and therefore NPA might be particularly effective against epileptiform activity.
Possible mechanism of action
In contrast to clinically established antiepileptic drugs, GABAA-and GABAB receptor agonists and non-neuronal GABA uptake blockers could block or reverse the LRDs in the entorhinal cortex. How can these effects be interpreted?
Upon prolonged seizure activity, inhibition becomes progressively weaker due to loss of synaptically available GABA (Schousboe et al., 1983; Gonsalves et al., 1989) . LRDs do not react to potentiating modulators of GABAA receptors which might indicate that the amount of synaptically released transmitter is already diminished during this late activity pattern (Mody et al., 1994) . Supplementing GABA receptor agonists should then be effective in restoring the inhibitory transmission which was indeed the case in our experiments. Secondly, a selective block of glial uptake would redirect extracellular GABA to the axonal endings of interneurones thereby preventing the metabolism of GABA by the GABA-transaminase in glia cells (Schousboe et al., 1983) . In contrast, a selective blockade of neuronal GABA uptake would aggravate the failure of inhibition. Our observations on the differential effects of NPA and fl-alanine versus tiagabine coincide with these predictions. We therefore support the hypothesis that depletion of synaptically available GABA might underlie the generation of the pharmacoresistant LRDs. A similar concept underlies the treatment of epilepsies with yvinyl-GABA, an irreversible blocker of the GABA transaminase which enhances the synaptic pool of GABA by closing the metabolic shunt (Ylinen et al., 1991; Buchanan, 1993; Petroff et al., 1995; Ben-Menachem, 1995) .
Antiepileptic effects on SLEs and RSDs
The SLEs in the EC are sensitive to most clinically employed antiepileptic drugs, whereas the RSDs in CAI react only to GABA agonists and valproic acid Zhang et al., 1995) . In accordance with previous findings (Jones, 1989) we found that GABA receptor agonists (GABA, muscimol and (-)-baclofen) were effective against RSDs and SLEs. Baclofen potently suppressed the entorhinal SLEs, but in contrast to previous findings (Jones, 1989) Baclofen was clearly more potent against RSDs in area CAl than against the seizure-like events in the mEC. Recent evidence suggests that GABAB receptors mediate a strong heterosynaptic inhibition of excitatory synaptic transmission in CAl (Isaacson et al., 1993) . This mechanism might explain the highly potent action of baclofen on RSDs. All uptake inhibitors tested effectively inhibited SLEs and RSDs. Most likely, this is caused by the prolongation of inhibitory postsynaptic potentials (Dingledine & Korn, 1985; Rekling et al., 1990; Thompson & Gahwiler, 1992; Oh & Dichter, 1994; Roepstorff & Lambert, 1994; Draguhn & Heinemann, unpublished) . The effect of tiagabine on the pharmacosensitive patterns of activity resembles the antiepileptic potency of this substance in animal models (Walton et al., 1994; Smith et al., 1995; Suzdak & Jansen, 1995) and man (Gram, 1994; Richens et al., 1995) . However, higher doses of tiagabine (50 and 250 gM) were ineffective against RSDs in CAl and even enhanced the frequency of the events. The underlying mechanism for this inverted concentration-response relationship remains to be elucidated. We cannot exclude the possibility that exposure to high doses of tiagabine finally results in a metabolic depletion of GABA, as suggested for the late entorhinal activity.
Pharmacological relevance
In summary, our experiments show that GABA receptor agonists and GABA uptake blockers potently suppress epileptiform activity in the hippocampus and entorhinal cortex. Upon prolonged synchronized hyperactivity, the selective neuronal GABA uptake blocker tiagabine loses its efficacy. This finding might point towards a loss of synaptically available GABA in axonal endings of interneurones. In this case, a selective block of the glial GABA uptake and thereby a redirection of GABA to the neuronal pool would be a more adequate strategy for antiepileptic drugs.
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